Invisible complications of sickle cell disease can result in a lack of understanding and proper care, says columnist.
The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...
Kanglin Biotechnology has raised $20 million in financing to advance the development of sickle cell gene therapy KL003.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback